Tag archive for ‘Bioequivalence study for Makena’
AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)
Importance of Makena SC to AMAG? AMAG is engaged in a high stakes clinical development program in which it is endeavoring to gain approval of a subcutaneous dosage form of its key drug Makena. Management has guided that sales of Makena reached $333 to $336 million in 2016 (about 63% of total sales) and issued […]